Unlocking life-threatening COVID-19 through two types of inborn errors of type I IFNs

Posted on | Posted on John Murphy | Leave a Comment on Unlocking life-threatening COVID-19 through two types of inborn errors of type I IFNs

Jean-Laurent Casanova1,2,3,4,5 and Mark S. Anderson6,7, Published February 1, 2023 – More infoView PDF Abstract Since 2003, rare inborn errors of human type I IFN immunity have been discovered, each underlying a few severe viral illnesses. Autoantibodies neutralizing type I IFNs due to rare inborn errors of autoimmune regulator (AIRE)–driven T cell tolerance were discovered in 2006, but not […]

Therapeutic potential of convalescent plasma and hyperimmune immunoglobulins against SARS-CoV-2 BQ.1, BQ.1.1, and XBB variants

Posted on | Posted on John Murphy | Leave a Comment on Therapeutic potential of convalescent plasma and hyperimmune immunoglobulins against SARS-CoV-2 BQ.1, BQ.1.1, and XBB variants

Lorenza Bellusci, Hana Golding, and Surender Khurana Journal of Clinical Investigation Published 2023 – More infoView PDF  Convalescent plasma (CP) and hyperimmune intravenous immunoglobulins (IVIGs) are routinely used to treat patients with COVID-19. SARS-CoV-2 Omicron variants continue to evolve, generating multiple sublineages with increased transmissibility and antibody-escape mutations (1, 2). Several Omicron lineages that are currently circulating (BA.4, BA.5, […]

The Unexpected Battle Between Vaccines And The COVID Virus

Posted on | Posted on John Murphy | Leave a Comment on The Unexpected Battle Between Vaccines And The COVID Virus

NOV 08, 2023 – Authored by Yuhong Dong The Epoch Times  Since the unprecedented COVID-19 global pandemic that started in January 2020, humans have been in a constant battle with the SARS-CoV-2 virus. A series of vaccine versions have been developed and administered globally, beginning in January 2021 when an mRNA vaccine based on the […]

C5aR1 signaling triggers lung immunopathology in COVID-19 through neutrophil extracellular traps

Posted on | Posted on John Murphy | Leave a Comment on C5aR1 signaling triggers lung immunopathology in COVID-19 through neutrophil extracellular traps

Bruna M. Silva,1,2 Giovanni F. Gomes,1 Flavio P. Veras,1 Seppe Cambier,3 Gabriel V.L. Silva,1,2 Andreza U. Quadros,1 Diego B. Caetité,1,2 Daniele C. Nascimento,1,2 Camilla M. Silva,1,2 Juliana C. Silva,1 Samara Damasceno,1 Ayda H. Schneider,1 Fabio Beretta,3 Sabrina S. Batah,4 Icaro M.S. Castro,5 Isadora M. Paiva,1 Tamara Rodrigues,1,2 Ana Salina,1,6 Ronaldo Martins,6,7 Guilherme C.M. Cebinelli,1,2 Naira L. Bibo,1 Daniel M. Jorge,6,7 Helder I. Nakaya,5 Dario S. Zamboni,1,6 Luiz O. Leiria,1,2 Alexandre T. Fabro,4 José C. Alves-Filho,1,2 Eurico Arruda,6,7 Paulo Louzada-Junior,1,8 Renê D. Oliveira,1,8 Larissa D. Cunha,1,6 Pierre […]

Treatments of COVID-19-Associated Taste and Saliva Secretory Disorders

Posted on | Posted on John Murphy | Leave a Comment on Treatments of COVID-19-Associated Taste and Saliva Secretory Disorders

Hironori Tsuchiya, Christos Rahiotis, Academic Editor and Nikolaos Gkantidis, Academic EditorDent J (Basel). 2023 Jun; 11(6): 140. Published online 2023 May 25. doi: 10.3390/dj11060140, PMCID: PMC10297082 PMID: 37366663 Abstract Since the worldwide spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, treating taste and saliva secretory disorders associated with coronavirus disease 2019 (COVID-19) has become a critical issue. The aim of the […]

COVID: The Science™ Concedes the Shots Cause Strokes

Posted on | Posted on John Murphy | Leave a Comment on COVID: The Science™ Concedes the Shots Cause Strokes

NOV 06, 2023 – Originally published  Armageddon Prose: COVID Shots Cause Strokes, The Science™ Concedes “Older adults who received last year’s COVID booster and a high-dose version of the flu vaccine in a recent study may have a potential increased risk of stroke, according to a new FDA-funded research project. Experts urged that the results […]

Time of day for COVID vaccine administration linked to clinical effectiveness

Posted on | Posted on John Murphy | Leave a Comment on Time of day for COVID vaccine administration linked to clinical effectiveness

Laura J. Rasmussen-Torvik, Published, 2023 – More infoView PDF  Journal of Clinical Investigation, Guy Hazan, … , David Greenberg, Jeffrey A. Haspel, Clinical Medicine COVID-19 Vaccines  In this issue of the JCI, Hazan et al. (1) report on whether time of day of COVID vaccination associates with subsequent breakthrough COVID-19 infection in 1,515,754 patients, using data from a large […]

Insurance Industry Execs ‘Alarmed’ by Surge in Deaths Among Young People — But Stop Short of Blaming COVID Shots

Posted on | Posted on John Murphy | Leave a Comment on Insurance Industry Execs ‘Alarmed’ by Surge in Deaths Among Young People — But Stop Short of Blaming COVID Shots

According to InsuranceNewsNet, insurers are especially concerned by data from the Centers for Disease Control and Prevention that show “mortality rates alarmingly rising for different categories,” including younger adult mortality rates that are up more than 20% above historic norms in 2023. By Mike Capuzzo, The Defender’s Top News of the Day.  Executives at the largest […]

A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes

Posted on | Posted on John Murphy | Leave a Comment on A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes

Theo Sanderson, Ryan Hisner, I’ah Donovan-Banfield, Hassan Hartman, Alessandra Løchen, Thomas P. Peacock & Christopher Ruis Nature (2023) Cite this article Abstract Molnupiravir, an antiviral medication widely used against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), acts by inducing mutations in the virus genome during replication. Most random mutations are likely to be deleterious to the virus and many will be lethal; thus, molnupiravir-induced […]

Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19A Randomized Clinical Trial

Posted on | Posted on John Murphy | Leave a Comment on Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19A Randomized Clinical Trial

Susanna Naggie, MD, MHS1,2; David R. Boulware, MD, MPH3; Christopher J. Lindsell, PhD4; et alThomas G. Stewart, PhD5; Alex J. Slandzicki, MD6; Stephen, C. Lim,  MD Jonathan Cohen, MD8;  David Kavtaradze, MD9,  Arch Amon, MD10, et. al for the Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group and Investigators. JAMA. 2023;329(11):888-897. doi:10.1001/jama.2023.1650 Question  Does ivermectin, with a maximum targeted dose of 600 μg/kg daily for 6 days, compared with placebo, shorten symptom duration among adult (≥30 years) outpatients with symptomatic […]